Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00004396 |
Recruitment Status
:
Completed
First Posted
: October 19, 1999
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
OBJECTIVES: I. Compare the efficacy of heme arginate, singly or in combination with tin mesoporphyrin, in lowering porphyrin precursors in patients with asymptomatic acute intermittent porphyria.
II. Evaluate and compare the safety and tolerability of these treatment regimens in this patient population.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Porphyria | Drug: heme arginate Drug: tin mesoporphyrin | Phase 2 |
PROTOCOL OUTLINE: This is an unblinded, dose ranging study. Patients receive heme arginate alone or in combination with tin mesoporphyrin.
Patients receive tin mesoporphyrin IV as a single dose. Heme arginate is administered as a single intravenous infusion.
Patients are entered in cohorts of 4. Subsequent cohorts of 4 patients each receive escalating doses of tin mesoporphyrin in combination with 1 of 2 different dosages of heme arginate. Subjects must maintain a constant diet.
Patients experiencing adverse reactions are followed as clinically indicated.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 32 participants |
Primary Purpose: | Treatment |
Study Start Date : | September 1997 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Documented acute intermittent porphyria in remission for at least 1 month
- Increased excretion of porphyrin precursors
- Absence of neurovisceral symptoms due to porphyria for at least 1 month
--Prior/Concurrent Therapy--
- At least 1 month since prior heme preparation therapy
- Concurrent medication for coexisting condition is allowed, as long as dose and pattern of administration is held constant during study
--Patient Characteristics--
- Renal: Urinary porphobilinogen excretion of at least 20 mg every 24 hours
- Other: Not pregnant Fertile female patients must use effective contraception during and at least 6 months before study At least 1 month since any symptoms of disease No concurrent acute hemorrhagic disorder such as: Gastrointestinal bleeding Intracerebral hemorrhage No known hypersensitivity to heme arginate, tin mesoporphyrin, another heme preparation, or related heme analogue No other condition that may increase risk to patient

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004396
United States, New York | |
Rockefeller University Hospital | |
New York, New York, United States, 10021-6399 | |
United States, Texas | |
University of Texas Medical Branch | |
Galveston, Texas, United States, 77555-0209 |
Study Chair: | Karl Elmo Anderson | University of Texas |
ClinicalTrials.gov Identifier: | NCT00004396 History of Changes |
Other Study ID Numbers: |
199/13185 UTMB-96-476 UTMB-96-318 UTMB-FDR000710 UTMB-FDR001459 |
First Posted: | October 19, 1999 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | December 2003 |
Keywords provided by National Center for Research Resources (NCRR):
inborn errors of metabolism porphyria rare disease |
Additional relevant MeSH terms:
Porphyrias Porphyria, Erythropoietic Metabolic Diseases Skin Diseases, Genetic Genetic Diseases, Inborn |
Skin Diseases Tin mesoporphyrin Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |